Table 1.
Clinical characteristics of patients and controls included in the study.
| MS total (%) | MS age-matched to controls (%) | Controls | |
|---|---|---|---|
| Patients (n) | 151 | 124 | 70 |
| Male (n) | 56 | 49 | 22 |
| Female (n) | 95 | 75 | 48 |
| Age (years) | 36.8 ± 9.8 | 33.7 ± 7.5 | 32.7 ± 13.1 |
| CIS (n (%)) | 10 (6.6%) | 9 (7.3%) | |
| RRMS (n (%)) | 123 (81,5%) | 104 (83.9%) | |
| PPMS (n (%)) | 4 (2.6%) | 3 (2.4%) | |
| SPMS (n (%)) | 14 (9.3%) | 8 (6.4%) | |
| Average EDSS | 2.87 ± 1.60 | 2.77 ± 1.57 | |
| Duration of disease (years) | 8.82 ± 6.67 | 8.10 ± 5.76 | |
| Treatment (n) | 83 | 69 | |
| cladribine | 12 | ||
| rituximab | 11 | ||
| natalisumab | 6 | ||
| glatiramer acetate | 23 | ||
| pegylated IFN-β | 31 | ||
| No treatment (n) | 68 | 55 | |
| Average MSSS | 4.28 ± 2.50 | 4.20 ± 2.43 | |
| MSSS 0-3 (n (%)) | 52 (34.4%) | 44 (35,5%) | |
| MSSS 3-6 (n (%)) | 48 (31.8%) | 40 (32.2%) | |
| MSSS 6-10 (n (%)) | 40 (26.5%) | 29 (23.4%) | |
| MSSS unknown | 11 (7.3%) | 11 (8.9%) |
CIS, clinically isolated syndrome, RRMS, relapsing remitting MS; PPMS, primary progressing MS; SPMS, secondary progressing MS; EDSS, Expanded Disability Status Scale; MSSS, Multiple Sclerosis Severity Score; n, number; % - percent from total number of patients. Data is presented as Mean ± SD.